Soluble B7-H3 as a Biomarker for Osteosarcoma
Last Update Posted : 2023-07-12
The aim of the trial
- A marker called B7-H3 has been associated with cancer. This marker could be used to monitor the effectiveness of cancer treatment. In this trial, osteosarcoma patients will have blood tests before and after treatment to measure B7-H3. They will look at whether the amount changes and if it can predict how well a person responds to the treatment. Being able to monitor if a treatment is working well will help to improve the treatment plan.
- Country
- China,
- Locations
- Beijing,
- Trial Type
- Observational
- Trial Phase
- -
- Trial Status
- Recruiting
- Minimum age
- 12 Years
- Maximum age
- -
- Key Contact
- -Lu Xie, M.D., +86-13401044719, xie.lu@hotmail.com,
- Clinical Trial ID
- NCT05942456
Key Information
- No new treatments are being tested in this trial. However, the results may lead to better cancer monitoring and treatment plans in the future.
How the treatment works
- No new treatment is given in this trial. People in this trial will receive standard treatment alongside the trial.
- Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.
Who is the trial for?
- The below points are a summary of who can enter the trial.
- People who have not had previous treatment for osteosarcoma.
- People who can tolerate chemotherapy.
Who is the trial not for?
- The below points are a summary of who can’t enter the trial.
- People without complete medical records in PKUPH system. Your doctor will know this.
- People with medical conditions that may put them at risk or affect the trial. The trial team will discuss this.
Disclaimer
- ONTEX is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team. If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from www.clinicaltrials.gov. The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and summarised the inclusion and exclusion criteria in the ‘who is this trial (not) for’ sections. To the best of our knowledge the clinical trial database is up-to-date and accurate.However, we cannot assume any liability for the accuracy or completeness of the information.